DARZALEX Q1 Sales Reach $3.96 Billion, Driving Genmab Royalty Income
GMAB sits 64% above its 52-week low of $17.575.
Summary
Genmab announced that worldwide net sales of DARZALEX, a key product for which it receives royalties from Johnson & Johnson, reached $3,964 million for the first quarter of 2026. This figure includes sales of both the intravenous and subcutaneous formulations of the drug. This is new, material information for investors, as DARZALEX sales are a significant component of Genmab's revenue stream. The reported sales provide an early indication of the company's financial performance for the quarter. Traders will be assessing this figure against market expectations and awaiting Genmab's full Q1 earnings report for a comprehensive financial picture.
At the time of this announcement, GMAB was trading at $28.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.3B. The 52-week trading range was $17.58 to $35.43. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.